JPRN-jRCT2052220049进行中（未招募）3 期
Aveir Dual-Chamber Leadless i2i IDE Study
icole Harbert0 个研究点目标入组 550 人开始时间: 2022年6月15日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 550
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Subject must have at least one of the clinical indications before device implant in adherence with ACC/AHA/HRS/ESC dual chamber pacing guidelines
- •2. Subject is 18 and over years of age or age of legal consent, whichever age is greater
- •3. Subject has a life expectancy of at least one year
- •4. Subject is willing to comply with clinical investigation procedures and agrees to return to clinic for all required follow-up visits, tests, and exams
- •5. Subject has been informed of the nature of the clinical investigation, agrees to its provisions and has provided a signed written informed consent, approved by the IRB/EC
排除标准
- •1. Subject is currently participating in another clinical investigation that may confound the results of this study as determined by the Sponsor
- •2. Subject is pregnant or nursing and those who plan pregnancy during the clinical investigation follow-up period
- •3. Subject has presence of anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigators opinion, could confound the assessment of the investigational device and/or implant procedure, limit the subjects ability to participate in the clinical investigation or to comply with follow-up requirements of the clinical investigation results
- •4. Subject has a known allergy or hypersensitivity to less than 1 mg of dexamethasone sodium phosphate or any blood or tissue contacting material listed in the IFU
- •5. Subject has an implanted vena cava filter or mechanical tricuspid valve prosthesis
- •6. Subject has pre-existing, permanent endocardial pacing or defibrillation leads (does not include lead fragments)
- •7. Subject has current implantation of either conventional or subcutaneous implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) device
- •8. Subject has an implanted leadless cardiac pacemaker (except for an Aveir ventricular LP)
- •9. Subject is implanted with an electrically-active implantable medical device with stimulation capabilities (such as neurological or cardiac stimulators)*
- •10. Subject is unable to read or write
- •*NOTE: Does not apply to a medical device with no known impact to the Aveir Leadless Pacemaker System, including the Aveir Link Module. Patient evaluation and the decision to implant the LP should take into account the presence of other active implantable devices and should include consultation with the Sponsor and/or manufacturer of the co-existing device.
研究者
相似试验
招募中
不适用
AveirTM DR i2i Study: Aveir Dual-Chamber Leadless i2i IDE Studyslow-heartratebradycardia10007521NL-OMON50262Abbott Medical25
进行中（未招募）
1 期
ESTUDIO DE FASE IIA, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO, DE DOCE SEMANAS DE DURACIÓN PARA EVALUAR LA SEGURIDAD, FARMACOCINÉTICA Y EFICACIA DE PH-797804 ADMINISTRADO POR VIA ORAL UNA VEZ AL DÍA EN PACIENTES CON ARTRITIS REUMATOIDE ACTIVAA 12-WEEK, PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF PH-797804, ADMINISTERED ORALLY ONCE DAILY IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS - n/aTratamiento de artritis reumatoide (AR)MedDRA version: 8.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2006-003577-27-ESPfizer S.A.290
进行中（未招募）
1 期
ESTUDIO DE FASE 2A ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO Y DE GRUPOS PARALELOS DE CE-224,535, UN ANTAGONISTA DEL RECEPTOR P2X7, EN EL TRATAMIENTO DE LOS SIGNOS Y SÍNTOMAS DE LA ARTRITIS REUMATOIDE EN PACIENTES CON UN CONTROL INADECUADO CON METROTEXATOA PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,PARALLEL-GROUP STUDY OF CE-224,535, AN ANTAGONIST OF THE P2X7RECEPTOR, IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OFRHEUMATOID ARTHRITIS IN SUBJECTS WHO ARE INADEQUATELYCONTROLLED ON METHOTREXATEArtritis ReumatoideMedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2008-000327-25-ESPFIZER S.A.78
进行中（未招募）
不适用
ESTUDIO DE FASE II, ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO Y DE GRUPOS PARALELOS PARA EVALUAR EL EFECTO DE IBODUTANT ORAL EN EL SÍNDROME DEL INTESTINO IRRITABLE CON DIARREA (SII-D) - Estudio IRIS-2 - IRIS-2SÍNDROME DEL COLON IRRITABLE CON DIARREA (SCI-D)MedDRA version: 12.1Level: LLTClassification code 10060849Term: Diarrhoea predominant irritable bowel syndromeEUCTR2010-018300-85-ESMenarini Ricerche S.p.A.900
进行中（未招募）
1 期
A PHASE II, DOUBLE-BLIND, CONTROLLED, PARALLEL-ARM TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INFUSION OF ALLOGENIC MESENCHYMAL STEM CELLS IN LUPUS NEPHRITIS (LN)PUS NEPHRITISMedDRA version: 20.0Level: PTClassification code 10025140Term: Lupus nephritisSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2017-000391-28-ESINSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEO